Decreased Expression of MIR-548c-3p in Osteosarcoma Contributes to Cell Proliferation Via Targeting ITGAV

Cancer Biotherapy and Radiopharmaceuticals

Volumn 31, Issue 5, 2016, Pages 153-158

  Luo, Zhanpeng ^a,b   Li, Dawei ^a,b   Luo, Xiaobo ^b   Li, Litao ^b   Gu, Suxi ^b   Yu, Long ^b   Ma, Yuanzheng ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b 309TH HOSPITAL OF PLA   (China)

Author keywords

apoptosis; cell cycle; ITGAV; MIR 548c 3p; osteosarcoma

Indexed keywords

CD51 ANTIGEN; MESSENGER RNA; MICRORNA; MICRORNA 548C 3P; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN548 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; OSTEOSARCOMA; PRIORITY JOURNAL; BIOSYNTHESIS; BONE TUMOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTEGRIN ALPHAV; MICRORNAS; OSTEOSARCOMA; TRANSFECTION;

EID: 84975516051     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2016.1995     Document Type: Article

References (29)

1. Vander Griend RA. Osteosarcoma and its variants. Orthop Clin North Am 1996;27:575.
2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776.
3. Isakoff MS, Bielack SS, Meltzer P, et al. Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol 2015;33:3029.
4. Taylor WF, Ivins JC, Pritchard DJ, et al. Trends and variability in survival among patients with osteosarcoma: A 7- year update. Mayo Clin Proc 1985;60:91.
5. SampsonVB, Yoo S,Kumar A, et al.MicroRNAs and potential targets in osteosarcoma: Review. Front Pediatr 2015;3:69.
6. Ginsberg MH, Partridge A, Shattil SJ. Integrin regulation. Curr Opin Cell Biol 2005;17:509.
7. Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci 2006;119:3901.
8. Nemeth JA, Nakada MT, Trikha M, et al. Alpha-v integrins as therapeutic targets in oncology. Cancer Invest 2007;25:632.
9. Stucci S, Tucci M, Passarelli A, et al. Avbeta3 integrin: Pathogenetic role in osteotropic tumors. Crit Rev Oncol Hematol 2015;96:183.
10. Cooper CR, Chay CH, Pienta KJ. The role of alpha(v)beta( 3) in prostate cancer progression. Neoplasia 2002;4:191.
11. Ha SY, Shin J, Kim JH, et al. Overexpression of integrin alphav correlates with poor prognosis in colorectal cancer. J Clin Pathol 2014;67:576.
12. Duperret EK, Dahal A, Ridky TW. Focal-adhesionindependent integrin-alphav regulation of FAK and c-Myc is necessary for 3D skin formation and tumor invasion. J Cell Sci 2015;128:3997.
13. Kaid C, Silva PB, Cortez BA, et al. miR-367 promotes proliferation and stem-like traits in medulloblastoma cells. Cancer Sci 2015;106:1188.
14. Schwickert A, Weghake E, Bruggemann K, et al. microRNA miR-142-3p inhibits breast cancer cell invasiveness by synchronous targeting of WASL, integrin alpha V, and additional cytoskeletal elements. PLoS One 2015;10:e0143993.
15. Ou J, Luan W, Deng J, et al. alphaV integrin induces multicellular radioresistance in human nasopharyngeal carcinoma via activating SAPK/JNK pathway. PLoS One 2012;7:e38737.
16. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1100.
17. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009;4:199.
18. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012;6:590.
19. Melo SA, Esteller M. Dysregulation of microRNAs in cancer: Playing with fire. FEBS Lett 2011;585:2087.
20. Curley GP, Blum H, Humphries MJ. Integrin antagonists. Cell Mol Life Sci 1999;56:427.
21. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91.
22. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J 2000;6 Suppl 3:S245.
23. He JM, Wang FC, Qi HB, et al. Down-regulation of alphav integrin by retroviral delivery of small interfering RNA reduces multicellular resistance of HT29. Cancer Lett 2009;284:182.
24. Mitjans F, Meyer T, Fittschen C, et al. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 2000;87:716.
25. Jia J, Starodub A, Cushman I, et al. Dual inhibition of alphaV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. Anticancer Drugs 2013;24:237.
26. Yang SY, Choi SA, Lee JY, et al. miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47. Oncotarget 2015;6:43712.
27. Piriyapongsa J, Jordan IK. A family of human microRNA genes from miniature inverted-repeat transposable elements. PLoS One 2007;2:e203.
28. Shi Y, Qiu M, Wu Y, et al. MiR-548-3p functions as an anti-oncogenic regulator in breast cancer. Biomed Pharmacother 2015;75:111.
29. Sun X, Cui M, Zhang A, et al. MiR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist. J Exp Clin Cancer Res 2016; 35:10.